IIn a recent study conducted by researchers at the University of Texas MD Anderson Cancer Center, the pulsed xenon UV light room disinfection system provided by Xenex Disinfection Services‘ novel technology successfully reduced the numver of patients who got infected by C.diff and VRE, which are antibiotic-resistant germs. According to Centers for Disease Control and Prevention (CDC), Clostridium difficile (C.diff) and Vancomycin-resistant Enterococcus (VRE) infect at least two million people and kill 23,000 people each year.
“Stopping infections before antibiotics are needed by destroying the deadly microorganisms that cause them is what can and should be done,” said Morris Miller, CEO of Xenex Disinfection Services. “Better hand hygiene and new antibiotics aren’t the only solutions — spores like C.diff can live in a patient room for 4-6 months. Xenex is the only UV disinfection company that’s been able to produce patient outcome data of hospitals experiencing fewer infections after using our devices to disinfect their facilities.”
In the C.diff study from January 2013, Xenex’s UV room-cleaning system could decrease C.diff infection by 26% compared to the current standard disinfection with bleach solution or sodium hypochlorite, which may damage hospital materials and may create a toxic environment. In the VRE study with Xenex UV disinfection device, no hospital associated-VRE (HA-VRE) infections were observed in Stem Cell Transplant (SCT) units for 5 months after implementing the system. In addition, the VRE infection rate decreased by 18% in the Leukemia units (UT).
The results presented in these studies are significant because they demonstrate that using pulsed xenon UV room disinfection technology to eliminate pathogens in the patient environment can lead to a reduction in patient infections,” said Dr. Mark Stibich, Chief Scientific Officer for Xenex. “These studies validate what we are hearing from many hospitals in the U.S. that are using the Xenex room disinfection system.”